Conference Call with Supriya Lifescience Management and Analysts on Q4FY24 Performance and Outlook. Listen to the full earnings transcript.
Conference Call with Supriya Lifescience Management and Analysts on Q2FY24 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Supriya Lifescience announced Q1FY24 results: Total revenue of Rs 134.9 crore in Q1FY24, as compared to Rs 103.7 crore in Q1FY23 Total PAT of Rs 28.51 crore in Q1FY24, as compared to Rs 25.25 crore in Q1FY23 Reported PAT margin of 22% Reported Gross profit of 64% EBITDA reported Rs 44.49 crore in Q1FY24, as compared to Rs 31.25 crore in Q1FY23 Healthy EBITDA margin of 34% reported in Q1FY24 Asian market contributed over 40% of the business, whereas Europe contributed 35% Satish Wagh, Chairman and Managing Director, Supriya Lifescience, commenting on their results said, “The company has been resilient to the global economic conditions and has delivered a strong comeback. Our strategic business initiatives of deeper penetration in existing markets and tapping new markets, backed by our world-class R&D; capabilities, have been the key growth drivers for our business. The demand from regulated markets like Europe, North America, and Latin America have surged and come back to normalcy.” Result PDF